Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.72 |
| ▸ | GART | P22102 | 6/20 | 0.70 |
| ▸ | FPGS | Q05932 | 2/20 | 0.64 |
| ▸ | DHFR | P00374 | 3/20 | 0.59 |
| ▸ | ATIC | P31939 | 4/20 | 0.55 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.54 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704421 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL258465 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL8060 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL29616598 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL13418310 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL3199681 | 1.00 | SOST (0.72) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL5829838 | 0.96 | SOST (0.66) | SOSTGARTFPGSDHFRATIC | |
| Tetrahydrofolate SCHEMBL18703989 | 0.94 | SOST (0.82) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL11475679 | 0.93 | SOST (0.62) | SOSTGARTFPGSDHFRATIC | |
| SCHEMBL8160135 | 0.93 | SOST (0.71) | SOSTGARTFPGSDHFRATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415837-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2024-12-19 | — | — | US | claimed |
| US-20240398857-A1 | COMPOSITIONS FOR MANAGEMENT OF HPV (HUMAN PAPILLOMA VIRUS) INFECTIONS | PAPILLEX INC. (CA) | 2024-12-05 | — | — | US | claimed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | claimed |
| EP-4419107-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | Machover, David (FR) | 2024-08-28 | — | — | EP | claimed |
| WO-2024051794-A1 | RADIONUCLIDE-DRUG CONJUGATE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 同宜医药（苏州）有限公司 | 2024-03-14 | — | — | WO | claimed |
| WO-2023202654-A1 | COMPOUND AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-10-26 | — | — | WO | claimed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | claimed |
| WO-2023078435-A1 | APPLICATION OF FOLIC ACID IN PREVENTION, DIAGNOSIS, AND TREATMENT OF HEREDITARY, INFECTIOUS, OR ALLERGIC DISEASES | 广州市妇女儿童医疗中心 | 2023-05-11 | — | — | WO | claimed |
| WO-2023066865-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2023-04-27 | — | — | WO | claimed |
| EP-4114399-A1 | FOLATE PREPARATIONS FOR THE TREATMENT OF OCULAR DISEASES | Aprofol AG (CH) | 2023-01-11 | — | — | EP | claimed |
| WO-2001030352-A1 | HIGH DOSE FOLIC ACID FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA | CARY PHARMACEUTICALS INC. (US) | 2001-05-03 | — | — | WO | claimed |
| US-6127370-A | INHIBITING OR PREVENTING MICROVASCULAR EVENTS LEADING TO ISCHEMIA AND/OR NEURODEGENERATION, SUCH AS OCCLUSIVE VASCULAR DISEASE OR ALZHEIMER'S DISEASE, IN PATIENTS HAVING ELEVATED BLOOD LEVELS OF HOMOCYSTEINE AND REDUCED LEVELS OF FOLATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-03 | — | — | US | claimed |
| US-6121195-A | STIMULATING CARBON FIXATION AND INCREASING THE GROWTH OF PLANTS BY ENHANCING THE AVAILABILITY OF C1-TETRAHYDROFOLATE IN THE LEAVES OF A PLANT | NONOMURA ARTHUR M (US) | 2000-09-19 | — | — | US | claimed |
| EP-0813510-A4 | METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS | NONOMURA ARTHUR M (US) | 2000-07-26 | — | — | EP | claimed |
| US-6008221-A | REDUCING HOMOCYSTEINE IN BLOOD LEVEL ON THE VASCULATURE OR ON NERVE CELLS IN THE BRAIN, DETOXIFICATION, TREATING NEURODEGENERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-28 | — | — | US | claimed |
| EP-0951293-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| US-5800979-A | Gas chromatography/mass spectrometric determination of folic acid coenzymes | KOLHOUSE J FRED (US) | 1998-09-01 | — | — | US | claimed |
| WO-1998019690-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-14 | — | — | WO | claimed |
| EP-0813510-A1 | METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS | NONOMURA, Arthur M. (US) | 1997-12-29 | — | — | EP | claimed |
| WO-1996027572-A1 | METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS | NONOMURA ARTHUR M (US) | 1996-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | SOST 1075/4885GART 256/4885FPGS 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.